We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bausch's (BHC) Q3 Earnings Beat Estimates, Revenues Miss
Read MoreHide Full Article
Shares of Bausch Health Companies Inc. (BHC - Free Report) were down 9.32% in response to third-quarter 2021 results.
The stock has gained 24.4% in the year so far against the industry’s decline of 5.9%.
Image Source: Zacks Investment Research
The company’s adjusted earnings per share of $1.14 beat the Zacks Consensus Estimate of $1.07 but decreased from $1.31 reported in the year-ago quarter.
Total revenues of $2.1 billion missed the Zacks Consensus Estimate by 1.95% and fell 1% year over year. Excluding the favorable impact of foreign exchange of $19 million and the impact of divestitures and discontinuations of $46 million, revenues were flat organically year over year.
Quarter in Detail
Revenues from the Bausch + Lomb segment were $949 million, up 4% year over year. Excluding the favorable impact of $10 million from foreign exchange and the impact of divestitures and discontinuations of $4 million, revenues increased organically by 3%, primarily due to higher sales resulting from the positive impacts of recovery from the COVID-19 pandemic.
Bausch Pharma (comprising Salix, International, Ortho Dermatologics, and Diversified Products) revenues were $1.16 billion, down 5% year over year. Salix segment revenues came in at $527 million, up 6%. Xifaxan sales increased 12%.
International Rx segment revenues in the quarter were $271 million, down 12%. Ortho Dermatologics segment revenues were $140 million in the quarter under review, down 2% year over year.
Diversified Products segment revenues were $224 million, down 19% from the year-ago quarter, primarily due to a decrease in volumes and net realized pricing.
During the third quarter, the company repaid debt by approximately $1.1 billion.
2021 Guidance Reiterated
Revenues are projected in the $8.40-$8.60 billion range.
Initial Public Offering of Solta Medical
On the last call, Bausch announced that it plans to pursue an initial public offering (IPO) of its Solta Medical business. Solta is a leading global provider in medical aesthetics with innovative and effective skin rejuvenation and body contouring solutions. The company expects to launch the proposed IPO of its Solta in December 2021 or January 2022. It also expects to launch the Bausch + Lomb IPO approximately 30 days later.
Pipeline Progress
Bausch announced statistically significant top-line results from the second phase III study evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction. The company expects to file an NDA with the FDA in the first half of 2022.
The company also completed the divestiture of Amoun Pharmaceutical Company S.A.E.
Bausch Health Cos Inc. Price, Consensus and EPS Surprise
Bausch beat on earnings in the third quarter but missed on sales. Nevertheless, management stated that many businesses continue to recover from the COVID-19 pandemic.
Image: Bigstock
Bausch's (BHC) Q3 Earnings Beat Estimates, Revenues Miss
Shares of Bausch Health Companies Inc. (BHC - Free Report) were down 9.32% in response to third-quarter 2021 results.
The stock has gained 24.4% in the year so far against the industry’s decline of 5.9%.
The company’s adjusted earnings per share of $1.14 beat the Zacks Consensus Estimate of $1.07 but decreased from $1.31 reported in the year-ago quarter.
Total revenues of $2.1 billion missed the Zacks Consensus Estimate by 1.95% and fell 1% year over year. Excluding the favorable impact of foreign exchange of $19 million and the impact of divestitures and discontinuations of $46 million, revenues were flat organically year over year.
Quarter in Detail
Revenues from the Bausch + Lomb segment were $949 million, up 4% year over year. Excluding the favorable impact of $10 million from foreign exchange and the impact of divestitures and discontinuations of $4 million, revenues increased organically by 3%, primarily due to higher sales resulting from the positive impacts of recovery from the COVID-19 pandemic.
Bausch Pharma (comprising Salix, International, Ortho Dermatologics, and Diversified Products) revenues were $1.16 billion, down 5% year over year. Salix segment revenues came in at $527 million, up 6%. Xifaxan sales increased 12%.
International Rx segment revenues in the quarter were $271 million, down 12%.
Ortho Dermatologics segment revenues were $140 million in the quarter under review, down 2% year over year.
Diversified Products segment revenues were $224 million, down 19% from the year-ago quarter, primarily due to a decrease in volumes and net realized pricing.
During the third quarter, the company repaid debt by approximately $1.1 billion.
2021 Guidance Reiterated
Revenues are projected in the $8.40-$8.60 billion range.
Initial Public Offering of Solta Medical
On the last call, Bausch announced that it plans to pursue an initial public offering (IPO) of its Solta Medical business. Solta is a leading global provider in medical aesthetics with innovative and effective skin rejuvenation and body contouring solutions. The company expects to launch the proposed IPO of its Solta in December 2021 or January 2022. It also expects to launch the Bausch + Lomb IPO approximately 30 days later.
Pipeline Progress
Bausch announced statistically significant top-line results from the second phase III study evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction. The company expects to file an NDA with the FDA in the first half of 2022.
The company also completed the divestiture of Amoun Pharmaceutical Company S.A.E.
Bausch Health Cos Inc. Price, Consensus and EPS Surprise
Bausch Health Cos Inc. price-consensus-eps-surprise-chart | Bausch Health Cos Inc. Quote
Our Take
Bausch beat on earnings in the third quarter but missed on sales. Nevertheless, management stated that many businesses continue to recover from the COVID-19 pandemic.
Zacks Rank & Stocks to Consider
Bausch currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare space are Regeneron Pharmaceuticals (REGN - Free Report) , Alkermes (ALKS - Free Report) , and Amicus Therapeutics (FOLD - Free Report) . While Regeneron and Alkermes sport a Zacks Rank #1 (Strong Buy), Amicus carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings estimates for Regeneron Pharmaceuticals moved up $1.86 for 2021 in the past 30 days. The stock is up 32.3% year to date.
Earnings estimates for Alkermes moved up 7 cents for 2021 in the past 30 days. The stock is up 48.9% year to date.
Loss estimates for Amicus have narrowed by 3 cents in the past 90 days.